Prothena PE Ratio 2011-2022 | PRTA

Current and historical p/e ratio for Prothena (PRTA) from 2011 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Prothena PE ratio as of February 03, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Prothena PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-02-03 57.75 0.00
2022-09-30 60.63 $-3.34 0.00
2022-06-30 27.15 $-0.24 0.00
2022-03-31 36.57 $1.22 29.98
2021-12-31 49.40 $1.09 45.32
2021-09-30 71.23 $1.03 69.16
2021-06-30 51.41 $-1.87 0.00
2021-03-31 25.12 $-3.11 0.00
2020-12-31 12.01 $-2.79 0.00
2020-09-30 9.99 $-2.56 0.00
2020-06-30 10.46 $-2.28 0.00
2020-03-31 10.70 $-2.02 0.00
2019-12-31 15.83 $-1.95 0.00
2019-09-30 7.84 $-1.97 0.00
2019-06-30 10.57 $-2.10 0.00
2019-03-31 12.13 $-3.20 0.00
2018-12-31 10.30 $-3.94 0.00
2018-09-30 13.08 $-4.62 0.00
2018-06-30 14.58 $-5.37 0.00
2018-03-31 36.71 $-4.33 0.00
2017-12-31 37.49 $-4.06 0.00
2017-09-30 64.77 $-4.23 0.00
2017-06-30 54.12 $-4.12 0.00
2017-03-31 55.79 $-4.84 0.00
2016-12-31 49.19 $-4.66 0.00
2016-09-30 59.97 $-4.01 0.00
2016-06-30 34.96 $-3.48 0.00
2016-03-31 41.16 $-2.89 0.00
2015-12-31 68.11 $-2.63 0.00
2015-09-30 45.34 $-2.35 0.00
2015-06-30 52.67 $-2.10 0.00
2015-03-31 38.14 $-1.45 0.00
2014-12-31 20.76 $-0.12 0.00
2014-09-30 22.16 $-0.16 0.00
2014-06-30 22.55 $-0.23 0.00
2014-03-31 38.31 $-0.93 0.00
2013-12-31 26.52 $-2.22 0.00
2013-09-30 20.23 $-2.52 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.794B $0.201B
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00